Treatment of Men With Major Depression: A Comparison of Sequential Cohorts Treated With Either Cognitive-Behavioral Therapy or Newer Generation Antidepressants
J Clin Psychiatry 2000;61:466-472
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: This report compares response to
cognitive-behavioral therapy (CBT) and pharmacotherapy in
sequential cohorts of men with DSM-III-R major depression.
Method: Patients were enrolled in consecutive
standardized 16-week treatment protocols conducted in the same
research clinic. The first group (N = 52) was treated with Beck's
model of CBT, whereas the second group (N = 23) received
randomized but open-label treatment with either fluoxetine (N =
10) or bupropion (N = 13). Crossover to the alternate medication
was permitted after 8 weeks of treatment for antidepressant
nonresponders. The patient groups were well matched prior to
treatment. Outcomes included remission and nonresponse rates, as
well as both independent clinical evaluations and self-reported
measures of depressive symptoms.
Results: Despite limited statistical power to
detect differences between treatments, depressed men treated with
pharmacotherapy had significantly greater improvements on 4 of 6
continuous dependent measures and a significantly lower rate of
nonresponse (i.e., 13% vs. 46%). The difference favoring
pharmacotherapy was late-emerging and partially explained by
crossing over nonresponders to the alternate medication. The
advantage of pharmacotherapy over CBT also tended to be larger
among the subgroup of patients with chronic depression.
Conclusion: Results of prior research comparing
pharmacotherapy and CBT may have been influenced by the
composition of study groups, particularly the gender composition,
the choice of antidepressant comparators, or an interaction of
these factors. Prospective studies utilizing flexible dosing of
modern antidepressants and, if necessary, sequential trials of
dissimilar medications are needed to confirm these findings.